Treatment of Melanoma Brain Metastases A New Paradigm

被引:37
作者
Carlino, Matteo S. [2 ,3 ]
Fogarty, Gerald B. [1 ,4 ]
Long, Georgina V. [1 ]
机构
[1] Melanoma Inst Australia, Sydney, NSW, Australia
[2] Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
[3] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia
[4] Mater Sydney Radiat Oncol Radiat Oncol Associates, Sydney, NSW, Australia
关键词
Metastatic melanoma; BRAF mutant; brain metastases; stage IV melanoma; stereotactic radiosurgery; BRAF inhibitors; GSK2118436; vemurafenib; ipilimumab; whole-brain radiotherapy; dabrafenib; DISSEMINATED MALIGNANT-MELANOMA; CEREBRAL METASTASES; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY; PROGNOSTIC-FACTORS; SINGLE METASTASES; RANDOMIZED-TRIAL; RADIOTHERAPY; MANAGEMENT; FOTEMUSTINE;
D O I
10.1097/PPO.0b013e31824b2890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Brain metastases occur commonly in patients with metastatic melanoma, are associated with a poor prognosis, and cause significant morbidity. Both surgery and stereotactic radiosurgery are used to control brain metastases and, in selected patients, improve survival. In those with extensive brain involvement, whole-brain radiotherapy can alleviate symptoms. Historically, systemic therapy has had little role to play in the management of melanoma brain metastases; however, early clinical trials of BRAF inhibitors have shown promising activity. This review examines the evidence for local and systemic treatments in the management of patients with melanoma brain metastases. We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors.
引用
收藏
页码:208 / 212
页数:5
相关论文
共 61 条
[1]   Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study [J].
Agarwala, SS ;
Kirkwood, JM ;
Gore, M ;
Dreno, B ;
Thatcher, N ;
Czarnetski, B ;
Atkins, M ;
Buzaid, A ;
Skarlos, D ;
Rankin, EM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2101-2107
[2]  
AMER MH, 1978, CANCER-AM CANCER SOC, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO
[3]  
2-E
[4]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[5]  
[Anonymous], J CLIN ONCOL S
[6]   Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial [J].
Aoyama, Hidefumi ;
Shirato, Hiroki ;
Tago, Masao ;
Nakagawa, Keiichi ;
Toyoda, Tatsuya ;
Hatano, Kazuo ;
Kenjyo, Masahiro ;
Oya, Natsuo ;
Hirota, Saeko ;
Shioura, Hiroki ;
Kunieda, Etsuo ;
Inomata, Taisuke ;
Hayakawa, Kazushige ;
Katoh, Norio ;
Kobashi, Gen .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2483-2491
[7]   Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].
Avril, MF ;
Aamdal, S ;
Grob, JJ ;
Hauschild, A ;
Mohr, P ;
Bonerandi, JJ ;
Weichenthal, M ;
Neuber, K ;
Bieber, T ;
Gilde, K ;
Porta, VG ;
Fra, J ;
Bonneterre, J ;
Saïag, P ;
Kamanabrou, D ;
Pehamberger, H ;
Sufliarsky, J ;
Larriba, JLG ;
Scherrer, A ;
Menu, Y .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125
[8]   The treatment of brain metastases in melanoma patients [J].
Bafaloukos, D ;
Gogas, H .
CANCER TREATMENT REVIEWS, 2004, 30 (06) :515-520
[9]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[10]  
BARRANCO SC, 1971, CANCER RES, V31, P830